OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+22.31%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$511M
AUM Growth
+$511M
(+3.3%)
Cap. Flow
+$46.3M
Cap. Flow
% of AUM
9.05%
Top 10 Holdings %
Top 10 Hldgs %
48.76%
Holding
68
New
20
Increased
11
Reduced
12
Closed
13
Top Buys
| 1 |
AFIB
Acutus Medical, Inc. Common Stock
AFIB
|
$22.4M |
| 2 |
Cardiff Oncology
CRDF
|
$16.2M |
| 3 |
Vaxcyte
PCVX
|
$15.5M |
| 4 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$10.4M |
| 5 |
Seres Therapeutics
MCRB
|
$9.49M |
Top Sells
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
$10.6M |
| 2 |
uniQure
QURE
|
$8.55M |
| 3 |
APTO
Aptose Biosciences, Inc.
APTO
|
$7.99M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$6.83M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$6.55M |
Sector Composition
| 1 | Healthcare | 92.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xoma
XOMA
$392M
| $8.57M | 1.68% | 455,000 +39,620 | +10% | +$746K |
|
27
Avalo Therapeutics
AVTX
$122M
| $7.68M | 1.5% | 3,372,500 | – | – |
|
|
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $7.43M | 1.45% | 114,350 | – | – |
|
|
ADMS
29
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $6.13M | 1.2% | 1,487,800 +527,800 | +55% | +$2.17M |
|
30
FibroGen
FGEN
$47.8M
| $6.05M | 1.18% | 147,000 +1,000 | +0.7% | +$41.1K |
|
31
TELA Bio
TELA
$70.5M
| $5.99M | 1.17% | 362,074 +112,074 | +45% | +$1.85M |
|
32
KalVista Pharmaceuticals
KALV
$678M
| $5.86M | 1.15% | 470,203 +8,703 | +2% | +$109K |
|
33
MEI Pharma
MEIP
$160M
| $4.86M | 0.95% | 1,556,000 | – | – |
|
|
EDAP
34
EDAP TMS
EDAP
$84.5M
| $4.78M | 0.94% | 1,040,000 -838,500 | -45% | -$3.86M |
|
35
Cytokinetics
CYTK
$4.23B
| $4.52M | 0.88% | 208,800 -94,250 | -31% | -$2.04M |
|
36
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.76M | 0.74% | 240,000 -195,200 | -45% | -$3.06M |
|
37
Fulcrum Therapeutics
FULC
$351M
| $3.58M | 0.7% | +452,000 | New | +$3.58M |
|
|
LUMO
38
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $3.33M | 0.65% | +240,892 | New | +$3.33M |
|
39
Kezar Life Sciences
KZR
$28.9M
| $3.28M | 0.64% | +678,000 | New | +$3.28M |
|
40
Verastem
VSTM
$569M
| $3.2M | 0.63% | +2,200,000 | New | +$3.2M |
|
41
Cidara Therapeutics
CDTX
$1.66B
| $2.77M | 0.54% | 970,664 | – | – |
|
42
Spyre Therapeutics
SYRE
$996M
| $2.66M | 0.52% | +375,000 | New | +$2.66M |
|
43
Minerva Neurosciences
NERV
$16.5M
| $2.44M | 0.48% | +767,400 | New | +$2.44M |
|
44
Outset Medical
OM
$247M
| $2.25M | 0.44% | +45,000 | New | +$2.25M |
|
45
ESSA Pharma
EPIX
$11.4M
| $1.87M | 0.37% | 271,350 +96,350 | +55% | +$665K |
|
46
Sutro Biopharma
STRO
$72.7M
| $1.47M | 0.29% | +146,000 | New | +$1.47M |
|
|
CFRX
47
DELISTED
ContraFect Corporation
CFRX
| $1.19M | 0.23% | +226,127 | New | +$1.19M |
|
|
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $982K | 0.19% | +100,000 | New | +$982K |
|
|
AMRN
49
Amarin Corp
AMRN
$311M
| $947K | 0.19% | 225,000 -230,000 | -51% | -$968K |
|
50
X4 Pharmaceuticals
XFOR
$84.3M
| $508K | 0.1% | +75,000 | New | +$508K |
|